Efficacy and Dose of IDegLira and iGlarLixi in Phase 3 Trials
| Population | Patients With Type 2 Diabetes Uncontrolled on Basal Insulin | Patients With Type 2 Diabetes Uncontrolled on a GLP-1 Receptor Agonist | ||||||
|---|---|---|---|---|---|---|---|---|
| Trial | DUAL II (47) | DUAL V (48) | LixiLan-L (50) | DUAL III (49) | ||||
| Treatment | IDegLira | Insulin degludec | IDegLira | Insulin glargine U100 | iGlarLixi | Insulin glargine U100 | IDegLira | Unchanged GLP-1 receptor agonist |
| n | 199 | 199 | 278 | 279 | 367 | 369 | 292 | 146 |
| A1C (%) | ||||||||
| Baseline | 8.7 (0.7) | 8.8 (0.7) | 8.4 (0.9) | 8.2 (0.9) | 8.1 (0.7) | 8.1 (0.7) | 7.8 (0.6) | 7.7 (0.5) |
| End of trial | 6.9 (NR) | 8.0 (NR) | 6.6 (0.9) | 7.1 (0.9) | 6.9 (0.9) | 7.5 (0.9) | 6.4 (0.8) | 7.4 (1.0) |
| Change | –1.9* (NR) | –0.9 (NR) | –1.81 (1.08) | –1.13 (0.98) | –1.1 (SE 0.06)* | –0.6 (SE 0.06) | –1.3 (0.9)* | –0.3 (0.9) |
| Responders (%) | ||||||||
| A1C <7% | 60.3* | 23.1 | 71.6* | 47.0 | 55* | 30 | 75* | 36 |
| A1C ≤6.5% | 45.2* | 13.1 | 55.4* | 30.8 | 34* | 14 | 63* | 23 |
| FPG (mg/dL) | ||||||||
| Baseline | 175 (52) | 173 (56) | 160.6 (47.5) | 159.8 (52.0) | 131.5 (36.0) | 133.3 (37.8) | 161.7 (38.2) | 169.1 (41.7) |
| End of trial | 112 (NR) | 126 (NR) | 109.5 (38.4) | 110.2 (38.6) | 122.5 (41.4) | 120.7 (37.8) | 108.5 (29.3) | 158.4 (48.7) |
| Change | –62 (53)* | –46 (60) | –50.9 (NR) | –49.9 (NR) | –7.2 (SE 1.8) | –9.0 (SE 1.8) | –53.6 (41.1)* | –10.7 (49.3) |
| End of trial dose (units) | 45 | 45 | 41 | 66 | 47 | 47 | 43 | NA |
Data are mean (SD) unless otherwise stated.
↵* Significant difference between treatments in favor of IDegLira/iGlarLixi.
NA, not applicable;
NR, not reported;
SE, standard error.